...
首页> 外文期刊>Asia-Pacific Biotech News >Bayer and Peking University establish new research center for translational research and drug discovery in Beijing
【24h】

Bayer and Peking University establish new research center for translational research and drug discovery in Beijing

机译:拜耳与北京大学在北京建立新的转化研究和药物发现研究中心

获取原文
获取原文并翻译 | 示例
           

摘要

Bayer HealthCareand Peking University (PKU), Beijing, China, have signed a comprehensive collaboration agreement on a three-year strategic partnership to promote translational research for drug discovery. Under this agreement, the two partners will establish a joint research center at Peking University under the name Bayer HealthCare/Peking University Center of Translational Research for Drug Discovery (BPC/TRDD)."Strategic alliances with international innovation partners from industry and academia are an essential element of our RftD strategy and complement our own research capabilities," said Prof. Dr. Andreas Busch, Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery. "The establishment of this research collaboration with Peking University also demonstrates Bayer's ongoing commitment to China as an important location in our innovation strategy. We are excited about the opportunity to collaborate with the excellent scientists at Peking University."
机译:中国北京的拜耳医药保健和北京大学(PKU)已签署一项为期三年的战略合作伙伴关系的全面合作协议,以促进药物发现的转化研究。根据该协议,这两个合作伙伴将在北京大学建立一个名为拜耳医药保健/北京大学药物发现转化研究中心(BPC / TRDD)的联合研究中心。“与来自工业界和学术界的国际创新伙伴建立战略联盟是我们RftD战略的重要组成部分,并补充了我们自身的研究能力。”拜耳医疗保健执行委员会成员兼全球药物开发负责人Andreas Busch博士说。 “与北京大学建立这项研究合作关系也证明了拜耳对中国作为我们创新战略中重要位置的持续承诺。我们很高兴有机会与北京大学的优秀科学家合作。”

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号